EMA Withdrawn: Zynquista (sotagliflozin) — Guidehouse Germany GmbH

View source ↗

Summary

The EMA withdrew Zynquista (sotagliflozin) from development/marketing for Type 1 diabetes, with Guidehouse Germany GmbH as the MAH, decision date 22 March 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Zynquista (sotagliflozin)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 1. MAH: Guidehouse Germany GmbH. Decision date: 22/03/2022